Brain Cancer Clinical Trials in Pittsburgh

Showing 181-181 of 181 trials

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

NCT00226668

The purpose of this study is to examine the safety and efficacy of XERECEPT (human Corticotropin-Releasing Factor, or hCRF) compared to dexamethasone in patients with primary malignant glioma who require increased dexamethasone doses to control symptom of peritumoral brain edema.

Brain EdemaBrain Tumor

Celtic Pharma Development Services120 participantsStarted Jan 2006

Phoenix, Arizona, United States • La Jolla, California, United States • Newport Beach, California, United States +23 more locations

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

Brain Cancer Trials in Other Cities

Other Conditions in Pittsburgh